Apimeds Pharmaceuticals US, Inc (APUS) investor relations documents from the company's IR site: 2 presentations, 7 press releases; latest deck 2025-07-15. Read in-app with summaries. First-party data.
Corporate Presentation: Apimeds Pharmaceuticals US, Inc. (APUS) is developing Apitox, a purified honeybee venom-based therapy, for knee osteoarthritis and MS-related pain.
| Published | Type | Document |
|---|---|---|
| 2026-05-05 | Press release | Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Ther |
| 2026-05-05 | Press release | Download as PDF |
| 2026-03-25 | Press release | Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc. |
| 2026-03-25 | Press release | Download as PDF |
| 2026-03-24 | Press release | Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds I |
| 2026-03-24 | Press release | Download as PDF |
| 2026-02-11 | Press release | Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox) |
| 2025-07-15 | Presentation | Corporate Presentation |
| 2024-11-08 | Fact sheet | Company Fact Sheet |
APUS overview · APUS earnings · APUS financials · APUS KPIs · APUS ownership · APUS peers · APUS filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.